Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Hoping to Win Time and Compliance, Asks Nasdaq to Be Transferred to Capital Market

NEW YORK (GenomeWeb News) – Transgenomic has asked the Nasdaq exchange to transfer its stock from the Global Market to the Capital Market in a bid to win time and regain compliance, according to documents filed with the Securities and Exchange Commission yesterday.
Transgenomic’s common stock does not meet Nasdaq's minimum $1 per share bid price to remain listed on the Global Market, the filing said.
The company had received notice from Nasdaq's Listing Qualifications Department on Feb. 15 saying it was in violation of its listing standards. Transgenomic had 180 days, or until Aug. 14, to regain compliance.
By moving to the Capital Market, Transgenomic would receive an additional 180 day grace period to increase its share price to satisfy the price requirement.

Nasdaq is expected to make a decision within two weeks, the filing said. Until the decision is announced, Transgenomic will continue to be listed on the Global Market.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.